Shire's Clear and Focused Strategy Delivers Record Quarterly Revenues. Non GAAP Diluted Earnings per ADS up 60%

Dublin (ots/PRNewswire) -

- Increases Non GAAP diluted earnings per ADS growth guidance to
the high thirty percent range for the full year (2014).

Shire announces unaudited results for the three months to
September 30, 2014.

Financial Highlights Q3 2014 Growth[1]
$1,552
Product sales million +33%[2]
$1,597
Total revenues million +32%
Non GAAP operating income $717 million +60%
US GAAP operating income from continuing operations $572 million +49%
Non GAAP EBITDA margin (excluding royalties & other
revenues)[3] 46% n/a
US GAAP net income margin[4] 30% n/a
Non GAAP diluted earnings per ADS $2.93 +60%
US GAAP diluted earnings per ADS $2.43 +66%
Non GAAP cash generation $612 million +27%
Non GAAP free cash flow $575 million +48%
US GAAP net cash provided by operating activities $593 million +37%

[1] Percentages compare to equivalent 2013 period. The 2013
comparatives in this release have been recast to exclude the
DERMAGRAFT(R) business from continuing operations following its
divestment on January 17, 2014.

[2]Product sales from continuing operations, including ViroPharma
Incorporated ("ViroPharma") acquired January 24, 2014, and excluding
the DERMAGRAFT business. Product sales excluding products acquired
with ViroPharma were up 19% in Q3 2014.

[3] Non GAAP earnings before interest, tax, depreciation and
amortization ("EBITDA") as a percentage of product sales, excluding
royalties and other revenues.

[4] US GAAP net income as a percentage of total revenues.

The Non GAAP financial measures included within this release are
explained on page 27, and are reconciled to the most directly
comparable financial measures prepared in accordance with US GAAP on
pages 20 - 25.

Susan Kilsby, Shire's Chairman, commented:

"Shire is well-positioned for future growth as we implement our
plan to double product sales to $10 billion by 2020. I am confident
that Shire, as an independent company, will deliver long-term value
to our shareholders and improved outcomes for patients. On behalf of
the Board of Directors, I would like to thank the Shire management
team and employees for the achievement of outstanding financial
results during the third quarter."

Flemming Ornskov, M.D., Shire's Chief Executive Officer,
commented:

"Our third quarter results demonstrate our exceptional track
record of delivering value and growth. We continue to implement our
clear and focused strategy, as we:

- Generated record quarterly product sales of $1,552 million, growing at 33%
- Grew Non GAAP diluted earnings per ADS by 60%, and
- Delivered Non GAAP cash generation of over $600 million.

"These results are a testament to our ability to drive top line
growth and our continued emphasis on operational discipline.

"We have seen strong sales performance across our portfolio with
all of our top ten products delivering double digit growth in the
quarter. Rare Diseases, our largest business unit, grew by 66%, aided
by our acquisition of ViroPharma. In our Hereditary Angioedema
portfolio, CINRYZE performed strongly with quarterly sales of $145
million and FIRAZYR was up 57%.

"Our Neuroscience and Gastrointestinal business units also
contributed to the record quarter with VYVANSE sales up 19% and
LIALDA up 24%.

"We continue to build our international presence and our expansion
into the Japanese market with the approval of VPRIV and AGRYLIN.

"Our early and late stage pipeline continues to be strengthened,
both internally, and through business development providing us with
new investments in Ophthalmology (BIKAM) and Rare Diseases (ArmaGen).
The US Food and Drug Administration accepted with priority review our
supplemental new drug application for VYVANSE as a treatment for
adults with binge eating disorder and we expect to learn about the
potential expanded indication in February 2015.

"Our strong momentum and performance this quarter is evidence of
our ability to deliver growth, efficiency and innovation through our
commitment to addressing significant unmet need in Rare Diseases and
high-value specialty conditions. As a result, I am pleased to once
again increase our guidance for 2014. We now expect to deliver Non
GAAP diluted earnings per ADS growth in the high thirty percent range
in 2014."

FINANCIAL SUMMARY

Third Quarter 2014 Unaudited Results

Q3 2014 Q3 2013
US GAAP Adjustments Non GAAP US GAAP Adjustments Non GAAP
$M $M $M $M $M $M
Total revenues 1,597 - 1,597 1,213 - 1,213
Operating income 572 145 717 383 66 449
Diluted earnings
per ADS $2.43 $0.50 $2.93 $1.46 $0.37 $1.83

- Product sales grew strongly in Q3 2014, up 33% to $1,552 million (Q3 2013:
$1,171 million). Product sales in Q3 2014 included $153 million for products acquired
with ViroPharma Incorporated ("ViroPharma"), primarily $145 million from CINRYZE(R).
The inclusion of ViroPharma contributed 14% to reported product sales growth in the
quarter.

Product sales grew 19% excluding products acquired with
ViroPharma. Growth was generated across our portfolio but primarily
driven by VYVANSE(R)[1] (up 19% to $355 million),
LIALDA(R)/MEZAVANT(R) (up 24% to $177 million), ELAPRASE(R) (up 31%
to $169 million) and REPLAGAL(R) (up 25% to $136 million). Sales of
ELAPRASE and REPLAGAL in the quarter benefitted from several large
orders from customers who order less frequently. In 2013 comparable
orders were recorded in the fourth quarter.

- Total revenues were up 32% to $1,597 million (Q3 2013: $1,213 million).
- On a Non GAAP basis:
Operating income grew strongly in Q3 2014, up 60% to $717 million (Q3 2013: $449
million) as combined Research and Development ("R&D") and Selling, General and
Administrative ("SG&A") costs increased at a much lower rate (up 10%) than total
revenues (up 32%).
On a Non GAAP basis:
EBITDA margin (excluding royalties and other revenues)[2]was 46%, up 8 percentage
points compared to Q3 2013 (Q3 2013: 38%), as we continue to deliver operating
leverage. R&D costs were 5% lower compared to Q3 2013. SG&A costs increased by 19%,
due in part to the inclusion of ViroPharma's SG&A costs and additional commercial
spending in advance of anticipated product launches for certain products.
On a US GAAP basis (from continuing operations):
Operating income was up 49% to $572 million (Q3 2013: $383 million), a lower rate of
increase than on a Non GAAP basis as Q3 2014 included higher amortization charges,
higher costs associated with acquisitions and integration activities as well as costs
associated with AbbVie's terminated offer for Shire. Combined R&D and SG&A was up 21%,
with R&D up 1% and SG&A up 32% as compared with Q3 2013. Net income margin in Q3 2014
was up 7 percentage points to 30% (Q3 2013: 23%).
- Non GAAP diluted earnings per American Depository Share ("ADS") increased 60%
to $2.93 (Q3 2013: $1.83) as a result of higher Non GAAP operating income and a lower
Non GAAP effective tax rate of 18% in Q3 2014 (Q3 2013: 20%).
On a US GAAP basis, diluted earnings per ADS increased 66% to $2.43 (Q3 2013:
$1.46) as a result of higher US GAAP operating income and a lower US GAAP effective
tax rate of 11% in Q3 2014 (Q3 2013: 20%).
- Cash generation, a Non GAAP measure, was up 27% to $612 million (Q3 2013: $482
million) reflecting higher receipts from product sales and lower operating expense
payments. Cash generation in Q3 2014 was held back by payments of $59 million in
respect of the final agreement with the US Government relating to previously disclosed
civil investigations, as well as payments in respect of the One Shire reorganization,
AbbVie's terminated offer for Shire and the integration of ViroPharma.
Free cash flow, also a Non GAAP measure, was up 48% to $575 million (Q3 2013: $388
million) due to higher cash generation and lower capital expenditure in the quarter.
On a US GAAP basis, net cash provided by operating activities was up 37% to $593
million (Q3 2013: $434 million).
- Net debt, also a Non GAAP measure, was $396 million at September 30, 2014
(December 31, 2013: net cash of $2,231 million).

On a US GAAP basis, cash and cash equivalents were $468 million at
September 30, 2014 (December 31, 2013: $2,239 million).

--------------------------------------------------

1. ) Lisdexamfetamine dimesylate ("LDX") currently marketed as
VYVANSE in the US and Canada, VENVANSE(R) in Latin America and
ELVANSE(R) in certain territories in the EU for the treatment of
ADHD. 2. ) EBITDA as a percentage of product sales, excluding
royalties and other revenues.

OUTLOOK

We've delivered a very strong performance so far this year, and as
a result we are increasing our guidance. We now expect to deliver Non
GAAP earnings per ADS growth in the high thirty percent range in 2014
(previous guidance: low-to-mid thirty percent growth).

Following our strong product sales performance in the year to
date, we now expect product sales growth for the full year 2014 in
the low twenty percent range (previous guidance: high teens growth).

We anticipate product sales growth in the fourth quarter to be
lower than we've delivered so far this year, as the third quarter
benefited from Rare Diseases sales to customers who order less
frequently, and as we lap against stronger comparatives in the fourth
quarter.

We expect royalties and other revenues for 2014 to be 0-5% lower
than in 2013, as we now anticipate recognizing additional milestone
income in the fourth quarter of 2014.

We continue to anticipate that our Non GAAP gross margin will be
approximately 1 percentage point lower than in 2013.

We continue to expect Combined Non GAAP R&D and SG&A to grow by
2-4% compared to 2013. We expect slightly higher operating costs in
the fourth quarter than seen in the third quarter, as we continue to
invest behind our innovative and exciting pipeline. The fourth
quarter will also see an increase in commercial spending on Binge
Eating Disorder disease awareness ahead of anticipated launch.

We continue to expect Non GAAP net interest expense to be
approximately $10 million lower than in 2013.

Our core effective tax rate on Non GAAP income is still expected
to be in the range of 17-19%.

Our current assumption of the diluted number of ordinary shares
for full year 2014 is approximately 590 million.

Taken together, we now expect to deliver Non GAAP earnings per ADS
growth in the high thirty percent range in 2014 (previous guidance:
low-to-mid thirty percent growth).

THIRD QUARTER 2014 AND RECENT PRODUCT AND PIPELINE DEVELOPMENTS

Products

We continue to make progress building our business in Japan:

- On September 26, 2014 Shire was granted a marketing authorization by the
Ministry of Health, Labour and Welfare in Japan for AGRYLIN(R)[1] in adult essential
thrombocythaemia patients.
- On September 2, 2014 Shire launched VPRIV(R) in Japan, for the improvement of
symptoms of Gaucher disease, following approval of a marketing authorization on July
4, 2014 by the Ministry of Health, Labor and Welfare in Japan.

VYVANSE - for the treatment of Binge Eating Disorder ("BED") in
adults

- On September 15, 2014 Shire announced that the US Food and Drug
Administration ("FDA") has accepted for filing with priority review a supplemental New
Drug Application ("sNDA") for VYVANSE as a treatment for adults with BED. The FDA is
expected to provide a decision in February 2015, based on the anticipated Prescription
Drug User Fee Act action date.

Pipeline

SHP607 - for the prevention of retinopathy of prematurity ("ROP")

- On October 17, 2014 Shire submitted an Investigational New Drug ("IND")
application for SHP607 with the FDA. The IND is subject to a 30-day review period.

SHP465 - for the treatment of ADHD in adults

- On October 9, 2014 Shire announced that it has received further guidance
from the FDA on the regulatory path for SHP465, an investigational oral stimulant
medication being evaluated as a potential treatment for ADHD in adults. This
information will impact Shire's plans for a 2014 New Drug Application ("NDA")
resubmission for SHP465.

SHP620 (maribavir) for the treatment of cytomegalovirus infection
("CMV") in transplant patients

- SHP620 was acquired as part of the acquisition of ViroPharma in Q1 2014.
Shire is currently conducting two Phase 2 studies in transplant recipients, both of
which are fully enrolled. The first is a trial in first-line treatment of asymptomatic
CMV in transplant recipients. The results showed that maribavir, at all doses, was at
least as effective as valganciclovir in the reduction of circulating CMV to below the
limits of assay detection (undetectable CMV). The second study is a trial for the
treatment of resistant/refractory CMV infection/disease in transplant recipients. The
purpose of this study is to determine whether maribavir is efficacious and safe in
patients with clinically refractory disease to standard of care CMV therapy (e.g.,
valganciclovir, foscarnet) with or without genotypic resistance to those agents.
Preliminary results are expected in early 2015. This product has been granted orphan
drug designation in both the US and EU.

[1] Currently marketed as XAGRID(R) in the EU for the treatment of
essential thrombocythaemia.

EXECUTIVE COMMITTEE CHANGES

- On October 20, 2014 Shire announced that James Bowling, Interim Chief
Financial Officer ("CFO"), had notified the Board of Directors of his decision to step
down from his current role to pursue a new career opportunity. James will leave Shire
at the end of Q1 2015 and Shire has commenced a search for a new CFO.

OTHER DEVELOPMENTS

Termination of AbbVie's offer for Shire

- On October 15, 2014 the Board of AbbVie confirmed that it had withdrawn
its recommendation of its offer for Shire as a result of the anticipated impact of the
US Treasury Notice on the benefits that AbbVie expected from its offer. As AbbVie's
offer was conditional on the approval of its stockholders, and given their Board's
decision to change its recommendation and to advise AbbVie's stockholders to vote
against the offer, there was no realistic prospect of satisfying this condition.
Accordingly, Shire's Board agreed with AbbVie to terminate the cooperation agreement
on October 20, 2014. The UK Takeover Panel has confirmed that the offer period has
ended. Shire has entered into a termination agreement with AbbVie, pursuant to which
AbbVie has paid the break fee under the cooperation agreement of approximately $1.635
billion.

Divestment of non-core product rights

During the third quarter Shire divested rights to three non-core
products for total cash consideration of $65 million.

- On September 30, 2014 Shire sold its rights to EXPUTEX(R) to Phoenix Labs
along with other specified assets.
- On August 1, 2014 Shire sold its rights to VANCOCIN(R) to ANI Pharmaceuticals
Inc. along with other specified assets.
- On July 17, 2014 Shire sold its rights to ESTRACE(R) to Trimel Pharmaceuticals
Inc. along with other specified assets.

Strategic licensing and collaboration agreement with ArmaGen
Technologies, Inc. ("ArmaGen")

- On July 23, 2014 Shire and ArmaGen, a US-based privately held
biotechnology company, announced a worldwide licensing and collaboration agreement to
develop and commercialize AGT-182, an investigational enzyme replacement therapy for
the potential treatment of both the central nervous system and somatic manifestations
in patients with Hunter syndrome. This collaboration strengthens Shire's rare disease
pipeline of innovative therapies where there is high unmet need, and underscores
Shire's long standing commitment to the Hunter syndrome community.

Strategic acquisition of BIKAM Pharmaceuticals Inc. ("BIKAM")

- On July 9, 2014 Shire acquired BIKAM, a US-based privately held
biotechnology company. The lead asset, SHP630 (formerly BIK-406), is in pre-clinical
development for the potential treatment of autosomal dominant retinitis pigmentosa.

Legal Proceedings

Shire reaches final agreement with US Government relating to
previously disclosed civil investigation

- On September 24, 2014 Shire announced that it had resolved all matters
with the US federal government, the 50 states and the District of Columbia relating to
a previously disclosed civil investigation of its US sales and marketing practices
relating to ADDERALL XR(R), VYVANSE, DAYTRANA(R), LIALDA and PENTASA(R). The
investigation was led by the US Attorney's Office for the Eastern District of
Pennsylvania. Under the agreement, Shire has paid $56.5 million, and interest, fees,
and costs, to resolve all issues investigated by the government. This final settlement
includes the resolution of two related qui tam complaints filed against Shire and a
voluntary disclosure relating to LIALDA and PENTASA. In addition, Shire has paid $2.9
million to resolve a previously disclosed civil complaint filed by the State of
Louisiana alleging that Shire's sales, marketing, and promotion of ADDERALL, ADDERALL
XR, DAYTRANA, VYVANSE and INTUNIV(R) violated state law. Shire recorded a $57.5
million provision related to these matters which was charged to SG&A in the fourth
quarter of 2012. As part of the resolution, Shire has entered into a Corporate
Integrity Agreement with the Office of Inspector General for the Department of Health
and Human Services for a term of five years.

ADDITIONAL INFORMATION

The following additional information is included in this press
release:

Page
Overview of Third Quarter 2014 Financial Results 7
Financial Information 11
Non GAAP Reconciliation 20
Notes to Editors 25
Safe Harbor Statement 26
Explanation of Non GAAP Measures 27
Trade Marks 28

Dial in details for the live conference call for investors at
14:00 BST / 09:00 EDT on October 24, 2014:

UK dial in: 0808 237 0030 or 0203 139 4830

US dial in: 1 866 928 7517 or 1 718 873 9077

International Access Numbers: Click here [http://wpc.1726.planets
tream.net/001726/FEL_Events_International_Access_List.pdf ]

Password/Conf ID: 40489933#

Live Webcast: Click here [http://event.onlineseminarsolutions.com
/r.htm?e=819579&s=1&k=49B3FECE7F0EC468D8286E2146662748 ]

The quarterly earnings presentation will be available today at
13:00 BST / 08:00 EDT on:

- Shire.com Investors section
[http://www.shire.com/shireplc/en/investors ]

- Shire's IR Briefcase in the iTunes Store
[https://itunes.apple.com/us/app/shire-ir-briefcase/id529486874?mt=8
]

Shire R&D day

Shire will hold an R&D day on December 10, 2014 in New York City.
For further details please contact the Shire Investor Relations team.

OVERVIEW OF THIRD QUARTER 2014 FINANCIAL RESULTS

1. Product sales

For the three months to September 30, 2014 product sales increased
by 33%[1] to $1,552 million (Q3 2013: $1,171 million) and represented
97% of total revenues (Q3 2013: 97%).

US Exit
Market
Year on year growth Share[3]
Non GAAP
Product sales[1] Sales $M Sales CER [2] US Rx [3]
VYVANSE 354.9 +19% +19% +5% 16%
LIALDA/MEZAVANT 176.6 +24% +24% +22% 32%
ELAPRASE 168.8 +31% +33% n/a[5] n/a[5]
CINRYZE[4] 145.1 n/a n/a n/a[5] n/a[5]
REPLAGAL 135.9 +25% +27% n/a[6] n/a[6]
FIRAZYR 98.4 +57% +57% n/a[5] n/a[5]
INTUNIV 96.7 +20% +20% +0% 4%
VPRIV 96.4 +10% +10% n/a[5] n/a[5]
ADDERALL XR 95.3 +17% +17% +12% 5%
PENTASA 78.3 +11% +11% -5% 13%
OTHER 105.6 -3% -5% n/a n/a
Total 1,552.0 +33% +33%

1) Product sales from continuing operations, including ViroPharma acquired
January 24, 2014, and excluding DERMAGRAFT which has been treated as discontinued
operations following divestment on January 17, 2014.
2) On a Constant Exchange Rate ("CER") basis, which is a Non GAAP measure.
3) Data provided by IMS Health National Prescription Audit ("IMS NPA") relates
solely to US-based prescriptions. Exit market share represents the average monthly US
market share in the month ended September 30, 2014.
4) CINRYZE product sales in Q3 2014 were up 36% on Q3 2013. Q3 2013 sales were
recorded by ViroPharma, prior to the acquisition of ViroPharma by Shire.
5) IMS NPA Data not available.
6) Not sold in the US in Q3 2014.

VYVANSE - ADHD

VYVANSE product sales grew strongly in Q3 2014 (up 19% compared to
Q3 2013) due to a price increase taken since Q3 2013 and to a lesser
extent higher US prescription demand and growth in international
markets.

LIALDA/MEZAVANT - Ulcerative Colitis

Product sales for LIALDA/MEZAVANT in Q3 2014 were up 24%,
primarily due to higher US prescription demand (up 22%) and to a
lesser extent a price increase taken since Q3 2013. Q3 2014 also
benefited from higher stocking than seen in Q2 2014.

ELAPRASE- Hunter syndrome

ELAPRASE product sales in Q3 2014 were up 31% compared to Q3 2013
driven by continued growth in the number of treated patients,
especially in emerging markets. Growth in Q3 2014 also benefited from
the timing of large shipments to certain markets which order less
frequently. Many of these comparable orders in 2013 were made in the
fourth quarter and therefore we expect ELAPRASE year-on-year sales
growth to moderate in Q4 2014.

CINRYZE - for the prophylactic treatment of Hereditary Angioedema
("HAE")

Shire acquired CINRYZE through its acquisition of ViroPharma in Q1
2014. CINRYZE sales were $145.1 million in Q3 2014, growing 36% on Q3
2013[(1)]primarily driven by more patients on therapy, inventory
build at specialty pharmacies favourably impacting sales and to a
lesser extent, a price increase in the US.

[1] Q3 2013 recorded by ViroPharma, prior to the acquisition of
ViroPharma by Shire.

REPLAGAL - Fabry disease

REPLAGAL sales were up 25% compared to Q3 2013 as we continue to
see good growth in emerging markets and to a lesser extent higher
volume demand in Europe. Q3 2014 also benefited from larger orders
for certain markets which order less frequently. A comparable order
in 2013 was made in the fourth quarter and therefore we expect
REPLAGAL year-on-year sales growth to moderate in Q4 2014.

FIRAZYR - for the treatment of acute HAE attacks

FIRAZYR's strong product sales growth (up 57%) was primarily due
to growth in patients on therapy and the effect of a price increase
in the US market.

INTUNIV - ADHD

The growth in INTUNIV product sales (up 20%) in Q3 2014 was driven
by price increases taken since Q3 2013, partially offset by
destocking in Q3 2014 as compared to stocking in Q3 2013. We expect
generic competition to enter the market starting in December 2014,
which would impact US sales of INTUNIV.

VPRIV - Gaucher disease

VPRIV product sales in Q3 2014 were up 10% compared to Q3 2013 as
we continue to add naive patients and gain patients switching from
other therapies.

ADDERALL XR - ADHD

ADDERALL XR product sales increased (up 17%) in Q3 2014, primarily
due to increased prescription demand, and lower sales deductions as a
percentage of product sales in Q3 2014 as compared to Q3 2013.

PENTASA - Ulcerative Colitis

PENTASA product sales increased in Q3 2014 (up 11%) driven by
price increases taken since Q3 2013 and a slight increase in
stocking.

2. Royalties

Year on year growth
Royalties to
Product Shire $M Royalties CER
FOSRENOL(R) 14.6 +6% +6%
ADDERALL XR 9.5 +53% +53%
3TC(R) and ZEFFIX(R) 8.8 -13% -13%
Other 7.0 -7% -7%
Total 39.9 +6% +6%

3. Financial details

Cost of product sales

% of % of
product product
Q3 2014 sales Q3 2013 sales
$M $M
Cost of product sales (US
GAAP) 254.3 16% 180.5 15%
Unwind of ViroPharma
inventory fair value
step-up (18.1) -
Depreciation (16.9) (10.2)
Cost of product sales (Non
GAAP) 219.3 14% 170.3 15%

Non GAAP cost of product sales as a percentage of product sales
decreased marginally in Q3 2014 as compared with Q3 2013.

US GAAP cost of product sales as a percentage of product sales
increased marginally in 2014 as Q3 2014 included charges on the
unwind of the fair value adjustment on acquired ViroPharma
inventories.

R&D

% of % of
product product
Q3 2014 sales Q3 2013 sales
$M $M
R&D (US GAAP) 228.6 15% 226.2 19%
Payments in respect of
in-licensed and acquired
products (12.5) -
Depreciation (6.1) (6.3)
R&D (Non GAAP) 210.0 14% 219.9 19%

Non GAAP R&D decreased by $9.9 million, or 5% in Q3 2014,
following the completion of several large Phase 3 programs since Q3
2013 including new uses for LDX and the effect of portfolio
prioritization decisions taken during 2013. These decreases were
partially offset by the inclusion of programs acquired through
business development in 2014.

US GAAP R&D increased by $2.4 million, or 1% as compared to Q3
2013.

SG&A

% of % of
product product
Q3 2014 sales Q3 2013 sales
$M $M
SG&A (US GAAP) 522.9 34% 396.3 34%
Intangible asset
amortization (62.9) (34.5)
Legal and litigation costs (3.3) (4.7)
Costs incurred in
connection with AbbVie's
terminated offer for Shire (28.4) -
Depreciation (20.7) (15.9)
SG&A (Non GAAP) 407.6 26% 341.2 29%

Non GAAP SG&A increased by $66.4 million, or 19%. The inclusion of
ViroPharma SG&A in Q3 2014 and commercial spending in advance of
anticipated product launches for certain products offset lower
ongoing overheads following the One Shire reorganization. Non GAAP
SG&A as a percentage of product sales was 3 percentage points lower
than Q3 2013 as we continue to see benefits from the One Shire
reorganization and the focus on operational discipline in Q3 2014.

US GAAP SG&A increased by $126.6 million, or 32%, as it also
includes higher amortization of intangible assets acquired with
ViroPharma, and costs incurred in connection with AbbVie's terminated
offer for Shire.

Gain on sale of product rights

For the three months to September 30, 2014 Shire recorded a net
gain on sale of non-core product rights of $46.0 million (2013: $3.6
million) following the divestment of VANCOCIN, ESTRACE and EXPUTEX.
The gain on sale of product rights also included the gain on
re-measurement of the contingent consideration receivable relating to
the divestment of DAYTRANA.

Reorganization costs

For the three months to September 30, 2014 Shire recorded
reorganization costs of $28.2 million (Q3 2013: $12.0 million)
related to the One Shire reorganization as we continue the
implementation of our new operating structure.

Integration and acquisition costs

For the three months to September 30, 2014 Shire recorded
integration and acquisition costs of $37.1 million, comprising a $4.9
million charge relating to the change in fair value of contingent
consideration liabilities and costs of $32.2 million primarily
related to the acquisition and integration of ViroPharma.

In Q3 2013 integration and acquisition costs ($18.4 million)
primarily related to the change in fair values of contingent
consideration liabilities and the cost of integrating SARcode
BioSciences Inc. ("SARcode") and Premacure AB ("Premacure").

Interest expense

For the three months to September 30, 2014 Shire incurred interest
expense of $6.8 million (Q3 2013: $9.2 million). Interest expense in
Q3 2014 primarily related to interest and the amortization of issue
costs incurred on borrowings to fund the ViroPharma acquisition.
Interest expense in Q3 2013 principally related to the coupon and
amortization of costs on Shire's convertible bonds which were fully
redeemed or converted in Q4 2013.

Taxation

The effective rate of tax on Non GAAP income in Q3 2014 was 18%
(Q3 2013: 20%), and on a US GAAP basis the effective rate of tax was
11% (Q3 2013: 20%).

The effective rate of tax in Q3 2014 on Non GAAP income from
continuing operations is lower than the same period in 2013 primarily
due to changes in profit mix.

The effective rate of tax in Q3 2014 on US GAAP income from
continuing operations is lower than the same period in 2013 primarily
due to changes in profit mix and the recognition of a further tax
credit of $27.7 million related to the settlement of an additional
position with the Canadian revenue authorities in Q3 2014.

Discontinued operations

The loss from discontinued operations for the three months to
September 30, 2014 was $36.1 million net of tax (2013: $22.9 million)
relating to costs associated with the divestment of the DERMAGRAFT
business, including a loss on re-measurement of contingent
consideration receivable from Organogenesis to its fair value.

FINANCIAL INFORMATION

TABLE OF CONTENTS

Page
Unaudited US GAAP Consolidated Balance Sheets 12
Unaudited US GAAP Consolidated Statements of Income 13
Unaudited US GAAP Consolidated Statements of Cash
Flows 15
Selected Notes to the Unaudited US GAAP Financial
Statements
(1) Earnings per share 17
(2) Analysis of revenues 18
Non GAAP reconciliation 20

Unaudited US GAAP financial position as of September 30, 2014
Consolidated Balance Sheets

September 30, December 31,
2014 2013
$M $M
ASSETS
Current assets:
Cash and cash equivalents 467.7 2,239.4
Restricted cash 54.5 22.2
Accounts receivable, net 1,079.3 961.2
Inventories 548.9 455.3
Assets held for sale - 31.6
Deferred tax asset 315.3 315.6
Prepaid expenses and other current assets 402.4 263.0
Total current assets 2,868.1 4,288.3
Non-current assets:
Investments 46.8 31.8
Property, plant and equipment ("PP&E"), net 845.6 891.8
Goodwill 2,373.7 624.6
Other intangible assets, net 5,227.4 2,312.6
Deferred tax asset 136.7 141.1
Other non-current assets 42.2 32.8
Total assets 11,540.5 8,323.0
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable and accrued expenses 1,725.8 1,688.4
Other current liabilities 276.6 119.5
Total current liabilities 2,002.4 1,807.9
Non-current liabilities:
Long term borrowings 850.0 -
Deferred tax liability 1,378.2 560.6
Other non-current liabilities 771.6 588.5
Total liabilities 5,002.2 2,957.0
Equity:
Common stock of 5p par value; 1,000 million
shares authorized; and 598.6 million shares
issued and outstanding (2013: 1,000 million
shares authorized; and 597.5 million shares
issued and outstanding) 58.7 58.6
Additional paid-in capital 4,302.0 4,186.3
Treasury stock: 10.8 million shares (2013: 13.4
million) (350.8) (450.6)
Accumulated other comprehensive income 30.8 110.2
Retained earnings 2,497.6 1,461.5
Total equity 6,538.3 5,366.0
Total liabilities and equity 11,540.5 8,323.0

Unaudited US GAAP results for the three months and nine months to
September 30, 2014 Consolidated Statements of Income

3 months to September 30, 9 months to September 30,
2014 2013 2014 2013
$M $M $M $M
Revenues:
Product sales 1,552.0 1,171.0 4,329.7 3,477.1
Royalties 39.9 37.6 101.4 112.4
Other revenues 5.2 4.1 14.9 18.8
Total revenues 1,597.1 1,212.7 4,446.0 3,608.3
Costs and expenses:
Cost of product sales 254.3 180.5 760.8 492.2
R&D[1] 228.6 226.2 826.0 703.3
SG&A[1] 522.9 396.3 1,449.4 1,198.0
Goodwill impairment charge - - - 7.1
Gain on sale of product
rights (46.0) (3.6) (86.2) (14.6)
Reorganization costs 28.2 12.0 123.4 47.2
Integration and acquisition
costs 37.1 18.4 155.8 39.9
Total operating expenses 1,025.1 829.8 3,229.2 2,473.1
Operating income from
continuing operations 572.0 382.9 1,216.8 1,135.2
Interest income 3.6 0.4 22.8 1.6
Interest expense (6.8) (9.2) (25.7) (27.5)
Other income/(expense), net 6.8 0.7 14.8 (1.6)
Total other
income/(expense), net 3.6 (8.1) 11.9 (27.5)
Income from continuing
operations before income
taxes and equity in
earnings/(losses) of equity
method investees 575.6 374.8 1,228.7 1,107.7
Income taxes (61.2) (73.4) 64.7 (235.3)
Equity in earnings/(losses)
of equity method investees,
net of taxes 1.4 (0.3) 3.8 0.6
Income from continuing
operations, net of tax 515.8 301.1 1,297.2 873.0
Loss from discontinued
operations, net of taxes (36.1) (22.9) (64.0) (271.9)
Net income 479.7 278.2 1,233.2 601.1

1) R&D includes intangible asset impairment charges of $188.0 million for
the nine months to September 30, 2014 (2013: $19.9 million). SG&A costs include
amortization charges of intangible assets relating to intellectual property rights
acquired of $62.9 million for the three months to September 30, 2014 (2013: $34.5
million) and $181.9 million for the nine months to September 30, 2014 (2013: $106.5
million).

Unaudited US GAAP results for the three months and nine months to
September 30, 2014 Consolidated Statements of Income (continued)

3 months to September 30, 9 months to September 30,
2014 2013 2014 2013
Earnings per Ordinary Share
- basic
Earnings from continuing
operations 87.8c 54.9c 221.3c 158.8c
Loss from discontinued
operations (6.1c) (4.2c) (10.9c) (49.5c)
Earnings per Ordinary Share
- basic 81.7c 50.7c 210.4c 109.3c
Earnings per ADS - basic 245.1c 152.1c 631.2c 327.9c
Earnings per Ordinary Share
- diluted
Earnings from continuing
operations 87.0c 52.7c 219.1c 152.5c
Loss from discontinued
operations (6.1c) (3.9c) (10.8c) (46.3c)
Earnings per Ordinary Share
- diluted 80.9c 48.8c 208.3c 106.2c
Earnings per ADS - diluted 242.7c 146.4c 624.9c 318.6c
Weighted average number of
shares:
Millions Millions Millions Millions
Basic 587.6 548.4 586.1 549.8
Diluted 592.6 585.7 592.1 587.5

Unaudited US GAAP results for the three months and nine months to
September 30, 2014 Consolidated Statements of Cash Flows

3 months to 9 months to
September 30, September 30,
2014 2013 2014 2013
$M $M $M $M
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income 479.7 278.2 1,233.2 601.1
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 106.6 78.2 307.1 229.4
Share based compensation 22.6 18.8 78.3 55.2
Change in fair value of contingent
consideration 4.9 14.7 26.3 28.4
Impairment of intangible assets - - 188.0 19.9
Goodwill impairment charge - - - 198.9
Write down of assets 1.0 - 14.0 8.3
Gain on sale of product rights (12.4) (3.6) (52.6) (14.6)
Unwind of ViroPharma inventory fair
value step-up 18.1 - 90.6 -
Other, net (1.9) (2.8) 16.5 (3.9)
Movement in deferred taxes 37.8 (5.1) 63.1 16.1
Equity in (earnings)/losses of equity method
investees (1.4) 0.3 (3.8) (0.6)
Changes in operating assets and liabilities:
Increase in accounts receivable (54.8) (112.6) (92.1) (215.2)
(Decrease)/increase in sales
deduction accrual (77.8) 68.7 28.2 108.7
(Increase)/decrease in inventory (4.1) 14.0 (15.8) (39.9)
Decrease/(increase) in prepayments
and other assets 22.8 (4.4) (114.7) (70.9)
Increase/(decrease) in accounts
payable and other liabilities 52.3 89.3 (92.8) (71.4)
Returns on investment from joint venture - - - 3.2
Net cash provided by operating
activities[A] 593.4 433.7 1,673.5 852.7

CASH FLOWS FROM INVESTING ACTIVITIES:
Movements in restricted cash (20.4) 1.0 (32.3) 0.5
Purchases of subsidiary undertakings and
businesses, net of cash acquired (86.1) - (4,104.4) (227.8)
Purchases of non-current investments (19.7) (3.1) (22.8) (9.9)
Purchases of PP&E (30.7) (45.3) (49.8) (110.3)
Proceeds from short-term investments 1.5 - 57.8 -
Proceeds from disposal of non-current
investments 13.3 0.9 21.3 8.6
Proceeds received on sale of product
rights 69.9 4.7 122.7 15.0
Other, net 4.1 0.1 1.3 2.9
Net cash used in investing
activities[B] (68.1) (41.7) (4,006.2) (321.0)

Unaudited US GAAP results for the three months and nine months to
September 30, 2014 Consolidated Statements of Cash Flows (continued)

3 months to September 9 months to September
30, 30,
2014 2013 2014 2013
$M $M $M $M
CASH FLOWS FROM FINANCING
ACTIVITIES:
Proceeds from revolving line of
credit, long term and short term
borrowings - - 2,310.8 -
Repayment of revolving line of
credit and short term borrowings (210.2) - (1,461.8) -
Repayment of debt acquired through
business combinations - - (551.5) -
Proceeds from ViroPharma call
options - - 346.7 -
Payment of dividend - - (99.6) (79.2)
Payments to acquire shares by the
Employee Benefit Trust ("EBT") - - - (50.3)
Payments to acquire shares under
the share buy-back program - (12.8) - (190.5)
Excess tax benefit associated with
exercise of stock options 8.3 3.4 37.4 9.5
Contingent consideration payments (2.5) (2.5) (12.8) (11.3)
Other, net (1.7) 1.7 (2.0) (5.5)
Net cash (used in)/provided by
financing activities[C] (206.1) (10.2) 567.2 (327.3)
Effect of foreign exchange rate
changes on cash and cash
equivalents [D] (5.1) 2.4 (6.2) (0.5)
Net increase/(decrease) in cash and
cash equivalents[(A) +(B) +(C)
+(D)] 314.1 384.2 (1,771.7) 203.9
Cash and cash equivalents at
beginning of period 153.6 1,301.9 2,239.4 1,482.2
Cash and cash equivalents at end of
period 467.7 1,686.1 467.7 1,686.1

Unaudited US GAAP results for the three months and nine months to
September 30, 2014

Selected Notes to the Financial Statements

(1) Earnings Per Share ("EPS")

3 months to September 30, 9 months to September 30,
2014 2013 2014 2013
$M $M $M $M
Income from continuing
operations 515.8 301.1 1,297.2 873.0
Loss from discontinued
operations (36.1) (22.9) (64.0) (271.9)
Numerator for basic EPS 479.7 278.2 1,233.2 601.1
Interest on convertible
bonds, net of tax - 7.6 - 22.7
Numerator for diluted EPS 479.7 285.8 1,233.2 623.8
Weighted average number of
shares:
Millions Millions Millions Millions
Basic[1] 587.6 548.4 586.1 549.8
Effect of dilutive shares:
Share based awards to
employees[2] 5.0 3.5 6.0 3.9
Convertible bonds[3] - 33.8 - 33.8
Diluted 592.6 585.7 592.1 587.5

1) Excludes shares purchased by the EBT and under the share buy-back program
and presented by Shire as treasury stock.
2) Calculated using the treasury stock method.
3) Calculated using the "if converted" method.

The share equivalents not included in the calculation of the
diluted weighted average number of shares are shown below:

3 months to September 30, 9 months to September 30,
2014 2013 2014 2013
Millions Millions Millions Millions
Share based awards to
employees[1] 0.3 0.5 0.3 4.5

1) Certain stock options have been excluded from the calculation of diluted
EPS because (a) their exercise prices exceeded Shire's average share price during the
calculation period or (b) the required performance conditions were not satisfied as at
the balance sheet date.

Unaudited US GAAP results for the three months to September 30,
2014

Selected Notes to the Financial Statements

(2) Analysis of revenues

3 months to September 30, 2014 2013 2014 2014
% % of total
$M $M change revenue
Net product sales:
VYVANSE 354.9 299.2 19% 22%
LIALDA/MEZAVANT 176.6 141.9 24% 11%
ELAPRASE 168.8 129.1 31% 11%
CINRYZE 145.1 - n/a 9%
REPLAGAL 135.9 108.5 25% 9%
FIRAZYR 98.4 62.6 57% 6%
INTUNIV 96.7 80.8 20% 6%
VPRIV 96.4 87.8 10% 6%
ADDERALL XR 95.3 81.4 17% 6%
PENTASA 78.3 70.6 11% 5%
FOSRENOL 48.1 51.9 -7% 3%
XAGRID 27.1 24.2 12% 2%
Other product sales 30.4 33.0 -8% 2%
Total product sales 1,552.0 1,171.0 33% 97%
Royalties:
FOSRENOL 14.6 13.8 6% <1%
ADDERALL XR 9.5 6.2 53% <1%
3TC and ZEFFIX 8.8 10.1 -13% <1%
Other 7.0 7.5 -7% <1%
Total royalties 39.9 37.6 6% 2%
Other revenues 5.2 4.1 27% <1%
Total revenues 1,597.1 1,212.7 32% 100%

Unaudited US GAAP results for the nine months to September 30,
2014

Selected Notes to the Financial Statements

(2) Analysis of revenues

9 months to September 30, 2014 2013 2014 2014
% % of total
$M $M change revenue
Net product sales:
VYVANSE 1,065.6 897.9 19% 24%
LIALDA/MEZAVANT 449.1 379.9 18% 10%
ELAPRASE 449.5 392.6 14% 10%
CINRYZE 360.6 - n/a 8%
REPLAGAL 380.7 336.6 13% 9%
FIRAZYR 262.3 153.8 71% 6%
INTUNIV 279.0 248.9 12% 6%
VPRIV 273.0 251.9 8% 6%
ADDERALL XR 280.2 293.5 -5% 6%
PENTASA 213.8 215.2 -1% 5%
FOSRENOL 136.2 136.3 0% 3%
XAGRID 82.1 74.1 11% 2%
Other product sales 97.6 96.4 1% 2%
Total product sales 4,329.7 3,477.1 25% 97%
Royalties:
FOSRENOL 36.8 33.6 10% 1%
ADDERALL XR 23.0 19.2 20% <1%
3TC and ZEFFIX 24.6 33.9 -27% 1%
Other 17.0 25.7 -34% <1%
Total royalties 101.4 112.4 -10% 2%
Other revenues 14.9 18.8 -21% <1%
Total revenues 4,446.0 3,608.3 23% 100%

Unaudited results for the three months to September 30, 2014

Non GAAP reconciliation

3 months to September
30, 2014 US GAAP Adjustments Non GAAP
(a) (b) (c) (d) (e) (f)
$M $M $M $M $M $M $M $M
Total revenues 1,597.1 - - - - - - 1,597.1
Costs and expenses:
Cost of product sales 254.3 - (18.1) - - - (16.9) 219.3
R&D 228.6 - (12.5) - - - (6.1) 210.0
SG&A 522.9 (62.9) - - (3.3) (28.4) (20.7) 407.6
Gain on sale of product
rights (46.0) - - 46.0 - - - -
Reorganization costs 28.2 - - (28.2) - - - -
Integration and
acquisition costs 37.1 - (37.1) - - - - -
Depreciation - - - - - - 43.7 43.7
Total operating expenses 1,025.1 (62.9) (67.7) 17.8 (3.3) (28.4) - 880.6
Operating income 572.0 62.9 67.7 (17.8) 3.3 28.4 - 716.5
Interest income 3.6 - - - - (2.8) - 0.8
Interest expense (6.8) - - - - - - (6.8)
Other expense, net 6.8 - (4.7) (10.8) - - - (8.7)
Total other
income/(expense), net 3.6 - (4.7) (10.8) - (2.8) - (14.7)
Income before income
taxes and equity in
earnings of equity
method investees 575.6 62.9 63.0 (28.6) 3.3 25.6 - 701.8
Income taxes (61.2) (29.5) (17.9) 13.9 (1.2) (27.7) - (123.6)
Equity in earnings of
equity method investees,
net of tax 1.4 - - - - - - 1.4
Net income from
continuing operations 515.8 33.4 45.1 (14.7) 2.1 (2.1) - 579.6
Loss from discontinued
operations, net of tax (36.1) - - 36.1 - - - -
Net income 479.7 33.4 45.1 21.4 2.1 (2.1) - 579.6
Weighted average number
of shares (millions) -
diluted 592.6 - - - - - - 592.6
Diluted earnings per ADS 242.7c 16.9c 22.9c 10.9c 1.2c (1.2c) - 293.4c

The following items are included in Adjustments:

a) Amortization and asset impairments: Amortization of intangible assets
relating to intellectual property rights acquired ($62.9 million), and tax effect of
adjustments;
b) Acquisition and integration activities: Unwind of ViroPharma inventory fair
value adjustments ($18.1 million), payments in respect of in-licensed and acquired
products ($12.5 million), costs primarily associated with the acquisition and
integration of ViroPharma ($32.2 million), net charge related to the change in fair
value of contingent consideration liabilities ($4.9 million), gain on settlement of
pre-existing relationship with an acquired business ($4.7 million), and tax effect of
adjustments;
c) Divestments, reorganizations and discontinued operations: Net gain on
divestment of non-core product rights and on re-measurement of DAYTRANA contingent
consideration to fair value ($46.0 million), costs relating to the One Shire
reorganization ($28.2 million), gain on sale of long term investments ($10.8 million),
tax effect of adjustments, and loss from discontinued operations, net of tax ($36.1
million);
d) Legal and litigation costs: Costs related to litigation, government
investigations, other disputes and external legal costs ($3.3 million), and tax effect
of adjustments;
e) Other: Costs associated with AbbVie's terminated offer for Shire ($28.4
million), interest income received in respect of cash deposited with the Canadian
revenue authorities ($2.8 million), net income tax credit related to the settlement of
certain tax positions with the Canadian revenue authorities ($27.7 million), and tax
effect of adjustments; and
f) Depreciation reclassification: Depreciation of $43.7 million included in Cost
of product sales, R&D and SG&A for US GAAP separately disclosed for the presentation
of Non GAAP earnings.

Unaudited results for the three months to September 30, 2013

Non GAAP reconciliation

3 months to September 30, 2013 US GAAP Adjustments Non GAAP
(a) (b) (c) (d) (e)
$M $M $M $M $M $M $M
Total revenues 1,212.7 - - - - - 1,212.7
Costs and expenses:
Cost of product sales 180.5 - - - - (10.2) 170.3
R&D 226.2 - - - - (6.3) 219.9
SG&A 396.3 (34.5) - - (4.7) (15.9) 341.2
Gain on sale of product rights (3.6) - - 3.6 - - -
Reorganization costs 12.0 - - (12.0) - - -
Integration and acquisition
costs 18.4 - (18.4) - - - -
Depreciation - - - - - 32.4 32.4
Total operating expenses 829.8 (34.5) (18.4) (8.4) (4.7) - 763.8
Operating income 382.9 34.5 18.4 8.4 4.7 - 448.9
Interest income 0.4 - - - - - 0.4
Interest expense (9.2) - - - - - (9.2)
Other expense, net 0.7 - - - - - 0.7
Total other expense, net (8.1) - - - - - (8.1)
Income before income taxes and
equity in losses of equity
method investees 374.8 34.5 18.4 8.4 4.7 - 440.8
Income taxes (73.4) (10.5) (1.0) (3.6) (1.8) - (90.3)
Equity in losses of equity
method investees, net